Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Demographic and rheumatoid arthritis disease characteristics

From: Abnormal networks of immune response-related molecules in bone marrow cells from patients with rheumatoid arthritis as revealed by DNA microarray analysis

Patient RA disease RF CRP steroid DMARDs
no. duration (years) (Unit/mL) (mg/dL) (mg/day)  
1 21 172 3.3 10 MTX 6 mg/week
2 24 99 2.0 5 Bucillamine 100 mg/day, MTX 4 mg/week
3 40 507 3.3 0 Actarit 200 mg/day
4 45 49 0.3 0  
5 9 324 2.6 4  
6 16 13 1.4 2.5 Bucillamine 100 mg/day
7 2 242 4.4 7.5 Salazosulfapyridine 1000 mg/day, MTX 6 mg/week
8 24 98 0.9 0 MTX 4 mg/week
9 17 40 2.9 5 MTX 6 mg/week
  1. CRP, C-reactive protein; DMARDs, disease-modifying antirheumatic drugs; MTX, methotrexate;
  2. RA, rheumatoid arthritis; RF, rheumatoid factor.